CatalystAlertBeta

Loading market movers...

All Therapeutic Areas

🛡️

Immunology & Inflammation

114 drugs in pipeline from 10 companies

114

Drugs in Pipeline

10

Companies

7

Upcoming Catalysts

114

Phase 3 Trials

Upcoming Catalysts

5d

JNJPhase 2$352.0B

✗Negative

Dupilumab Phase 2 Results Expected

Dupilumab• Dermatitis, Atopic256

Mar 9Estimated

2w

KYTXPhase 2$360M

Standard lymphodepletion regimen Phase 2 Results Expected

Standard lymphodepletion regimen• Lupus Nephritis3

Mar 15Estimated

00%

2w

ABVXPhase 2$10.3B

ABX464 Phase 2 Results Expected

ABX464• Ulcerative Colitis203

Mar 15Estimated

00%

2w

GILDPhase 2$60.0B

GS-1427 Phase 2 Results Expected

GS-1427• Ulcerative Colitis228

Mar 15Estimated

00%

2w

ANROPhase 2$590M

PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days Phase 2 Results Expected

PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days• Bronchial Asthma30

Mar 15Estimated

00%

2w

REGNPhase 3$113.8B

Placebo Phase 3 Results Expected

Dupilumab• Atopic Dermatitis (AD)1,546

Mar 16Estimated

00%

4w

CELG-RIPhase 2

Afimetoran Phase 2 Results Expected

Afimetoran• Systemic Lupus Erythematosus268

Mar 29Estimated

00%

View all catalysts

Pipeline by Phase

Phase 3

114

Active Companies

Biogen Inc.

Amgen Inc.

Novartis AG

GSK plc

AstraZeneca PLC

Roche Holding AG

NOVARTIS AG

Sanofi

Eli Lilly and Company

ABBOTT LABORATORIES

Related Conditions

autoimmunerheumatoid arthritislupuspsoriasiscrohnulcerative colitisibdinflammatoryimmuneimmunologyeczemadermatitisankylosing spondylitismultiple sclerosisgrafttransplantrejectionallergyasthma